Percutaneous treatment of a dysfunctional aortic bioprosthesis with the CoreValve(®) prosthesis

Rev Esp Cardiol. 2011 Feb;64(2):155-8. doi: 10.1016/j.recesp.2010.03.001. Epub 2011 Jan 3.
[Article in English, Spanish]

Abstract

Recently, percutaneous aortic valve replacement has emerged as a therapeutic option for patients with severe symptomatic aortic stenosis and a high surgical risk. We report our initial experience in four patients with percutaneous implantation of a CoreValve aortic prosthesis to treat aortic bioprosthesis dysfunction involving aortic stenosis or regurgitation. In-hospital and medium-term outcomes were analyzed. The procedure was performed under local anesthesia and guided by angiography. The prosthesis was implanted successfully in all patients, although a second prosthesis was required in one case because the first was positioned too high. There were no major complications. After a mean follow-up of 7 months (SD, 4.7), all patients remained asymptomatic.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Aortic Valve Insufficiency / surgery
  • Aortic Valve Stenosis / surgery
  • Bioprosthesis*
  • Coronary Angiography
  • Female
  • Heart Valve Prosthesis Implantation / methods*
  • Heart Valve Prosthesis*
  • Humans
  • Male
  • Middle Aged
  • Prosthesis Failure
  • Reoperation
  • Surgery, Computer-Assisted
  • Treatment Outcome